Risk of miscarriage with bivalent vaccine against human papillomavirus (HPV) types 16 and 18: Pooled analysis of two randomised controlled trials

BMJ (Online)

Volumn 340, Issue 7748, 2010, Pages 696-

  Wacholder, Sholom ^a   Chen, Bingshu Eric ^b   Wilcox, Allen ^c   Macones, George ^d   Gonzalez, Paula ^e   Befano, Brian ^f   Hildesheim, Allan ^a   Rodríguez, Ana Cecilia ^e   Solomon, Diane ^a   Lowy, Douglas R ^a   Schiffman, Mark ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b QUEEN S UNIVERSITY   (Canada)

^c NATIONAL INSTITUTE OF ENVIRONMENTAL HEALTH SCIENCES   (United States)

^d WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e PROYECTO EPIDEMIOLÓGICO GUANACASTE   (Costa Rica)

^f INFORMATION MANAGEMENT SERVICES INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

HEPATITIS A VACCINE; WART VIRUS VACCINE;

ADOLESCENT; ADULT; ARTICLE; CLINICAL TRIAL; CONCEPTION; CONDYLOMA ACUMINATUM; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COSTA RICA; DRUG EFFICACY; FEMALE; HUMAN; HUMAN PAPILLOMAVIRUS TYPE 16; HUMAN PAPILLOMAVIRUS TYPE 18; LIVE BIRTH; PREGNANCY OUTCOME; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RISK ASSESSMENT; SPONTANEOUS ABORTION; VACCINATION;

EID: 77950258317     PISSN: None     EISSN: 17561833     Source Type: Journal    
DOI: 10.1136/bmj.c712     Document Type: Article

References (13)

1. ParkinDM, Bray F, Ferlay J, Pisani P. Global cancer statistics, 2002. CA Cancer J Clin 2005;55:74-108.
2. Schiffman M, Castle PE, Jeronimo J, Rodriguez AC, Wacholder S. Human papillomavirus and cervical cancer. Lancet 2007;370:890-907.
3. Paavonen J, Jenkins D, Bosch FX, Naud P, Salmeron J, Wheeler CM, et al. Efficacy of a prophylactic adjuvanted bivalent L1 virus-likeparticle vaccine against infection with human papillomavirus types 16 and 18 in youngwomen: an interim analysis of a phase III doubleblind, randomised controlled trial. Lancet 2007;369:2161-2170
4. FUTURE II Study Group. Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions. N Engl JMed 2007;356:1915-1927
5. Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, et al. Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.N Engl J Med 2007;356:1928-1943
6. Centers for Disease Control and Prevention. ACIP: guidance for vaccine recommendations in pregnant and breastfeeding women. CDC, 2008. www.cdc.gov/vaccines/recs/acip/rec-vac-preg.htm.
7. Goldhaber MK, Fireman BH. The fetal life table revisited: spontaneous abortion rates in three Kaiser Permanente cohorts. Epidemiology 1991;2:33-39
8. Sjoborg KD, Eskild A. Vaccination against human papillomavirus- an impact on preterm delivery? Estimations based on literature review. Acta Obstet Gynecol Scand 2009;88:255-260
9. Herrero R, Hildesheim A, Rodriguez AC, Wacholder S, Bratti C, Solomon D, et al. Rationale and design of a community-based double-blind randomized clinical trial of anHPV 16 and 18 vaccine in Guanacaste, Costa Rica. Vaccine 2008;26:4795-4808
10. Wilcox AJ. Fertility and pregnancy: an epidemiologic perspective. Oxford University Press, 2010.
11. Centers for Disease Control and Prevention. Guidelines for vaccinating pregnant women-human papillomavirus. CDC, 2008. www.cdc.gov/vaccines/pubs/preg- guide.htm#hpv.
12. Markowitz LE, Dunne EF, Saraiya M, Lawson HW, Chesson H, Unger ER. Quadrivalent human papillomavirus vaccine: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep 2007;561-624
13. Baird DD, McConnaughey DR, Weinberg CR, Musey PI, Collins DC, Kesner JS, et al. Application of a method for estimating day of ovulation using urinary estrogen and progesterone metabolites. Epidemiology 1995;6:547-550